Several pre-clinical and clinical studies have provided evidence that anti-platelet therapies, such as the P2Y12 antagonists clopidogrel and ticagrelor, slow down the progression of HCC by suppressing the intra-hepatic inflammatory response [31,32,33]. Here, P2RY12 is linked to hepatocellular carcinoma.